Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Multiple Myeloma 2121Neoplasms, Plasma Cell 505Lymphoma 354Lymphoma, Non-Hodgkin 334Hodgkin Disease 329Leukemia, Lymphocytic, Chronic, B-Cell 307Precursor Cell Lymphoblastic Leukemia-Lymphoma 299Leukemia 290Leukemia, Myeloid, Acute 270Myelodysplastic Syndromes 263Lymphoma, Mantle-Cell 228Lymphoma, Follicular 224Lymphoma, Large B-Cell, Diffuse 216Lymphoma, B-Cell, Marginal Zone 206Burkitt Lymphoma 201Recurrence 188Myeloproliferative Disorders 182Lymphoma, Large-Cell, Immunoblastic 182Immunoglobulin Light-chain Amyloidosis 162Primary Myelofibrosis 153Leukemia, Myeloid, Chronic-Phase 152Leukemia, Myeloid, Accelerated Phase 143Lymphoma, T-Cell, Cutaneous 140Leukemia, Myelomonocytic, Chronic 133Blast Crisis 131Mycosis Fungoides 126Sezary Syndrome 125Congenital Abnormalities 122Waldenstrom Macroglobulinemia 121Leukemia, Hairy Cell 110

Interventions

Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Heart Failure, Systolic × Plasma cell × Clear all
NCT02026505 2019-03-13

Evaluation of Cardiotoxic Effects of Bortezomib

Oregon Health and Science University

Completed
11 enrolled
Plasma cell

Multiple Myeloma, Heart Failure, Systolic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡